Zolbetuximab is a recombinant chimeric monoclonal antibody targeting Claudin-18.2 (CLDN18.2), a cell-surface protein expressed in selected gastrointestinal and other solid tumors. Zolbetuximab is also known by the development code IMAB362 and the synonym claudiximab. The U.S. FDA Substance Registration System identifies zolbetuximab under CAS No. 1496553-00-4.
Zolbetuximab is an IgG1 monoclonal antibody consisting of antibody variable regions directed against human Claudin-18.2 together with human IgG1 constant regions. Regulatory documentation describes the molecule as a chimeric mouse/human antibody with an approximate molecular weight of 147 kDa.
Claudin-18.2, commonly abbreviated as CLDN18.2, is a tight-junction-associated protein that has attracted significant interest as a molecular target in oncology research. Zolbetuximab specifically recognizes CLDN18.2 and has been developed as a targeted monoclonal antibody for tumors expressing this antigen.
The therapeutic product VYLOY (zolbetuximab-clzb) was approved in the United States in 2024, and the European Medicines Agency lists VYLOY as a medicine containing zolbetuximab for the treatment of relevant gastrointestinal cancers.
Unlike conventional low-molecular-weight pharmaceutical APIs, zolbetuximab is a biological drug substance. Its quality cannot be adequately described using only traditional tests such as melting point, residue on ignition or a conventional 98–102% HPLC assay.
The quality evaluation of monoclonal antibodies normally considers multiple critical quality attributes, including molecular identity, protein concentration, purity, molecular-size distribution, charge variants, structural characteristics, biological activity and product-related impurities.
The EMA assessment report states that the specifications for zolbetuximab finished product are established according to ICH Q6B and cover identity, content, potency, purity, impurities and safety.
Zolbetuximab is produced as a recombinant monoclonal antibody. Regulatory documentation identifies the antibody as a chimeric mouse/human IgG1 molecule. The commercial drug product is manufactured as a sterile lyophilized powder for intravenous administration.
Analytical characterization of monoclonal antibodies can include peptide mapping, mass spectrometry, chromatographic methods, electrophoretic methods, charge-variant analysis and biological binding or functional assays. These techniques provide information that is more relevant to a complex protein therapeutic than conventional small-molecule API testing.
For zolbetuximab, purity and potency should not be represented by a generic HPLC percentage. Regulatory specifications evaluate multiple quality attributes.
The EMA assessment specifically states that zolbetuximab potency is controlled using ADCC (antibody-dependent cellular cytotoxicity) and CDC (complement-dependent cytotoxicity) assays. This reflects the biological mechanism of the antibody and provides functional confirmation of its activity.
Research-grade zolbetuximab products may report purity values such as 99% or higher, but those figures should not be presented as the commercial pharmaceutical release specification unless supported by the applicable manufacturer's CoA or regulatory specification. For example, a research-grade supplier reports 99% purity and approximately 150 kDa molecular weight, but explicitly labels the material for research use only.
The approved VYLOY product is supplied as a white to off-white lyophilized powder in single-dose vials. The U.S. product is available in 100 mg and 300 mg vial presentations.
After reconstitution with Sterile Water for Injection, the product produces a clear to slightly opalescent, colorless to slightly yellow solution with a final zolbetuximab concentration of 20 mg/mL. The formulation is adjusted to pH 6.0.
The 100-mg vial is reconstituted with 5 mL of Sterile Water for Injection, while the 300-mg vial is reconstituted with 15 mL, with both resulting in a nominal concentration of 20 mg/mL.
Quality control for a monoclonal antibody such as zolbetuximab should include appropriate analytical and biological methods. Important quality attributes can include:
These attributes are controlled using validated analytical methods appropriate to the product and regulatory filing. EMA documentation confirms that the zolbetuximab specification covers identity, content, potency, purity, impurities and safety.
Organizations involved in biologics development and pharmaceutical manufacturing should specify the exact zolbetuximab material required, including whether the requirement relates to research material, biological drug substance or finished pharmaceutical product.
Documentation requirements may include a Certificate of Analysis, analytical characterization package, Safety Data Sheet, stability information, quality specification and applicable regulatory documentation.
Because zolbetuximab is a biological molecule, its quality specification should be based on the applicable regulatory dossier and validated analytical methods rather than generic specifications intended for conventional small-molecule APIs.
Swapnroop Drugs and Pharmaceuticals describes its business as a supplier and exporter of pharmaceutical raw materials, APIs and related pharmaceutical products, with a WHO-GMP-certified manufacturing and export focus. Its website states that the company serves pharmaceutical manufacturers, formulation companies, research organizations and other customers internationally.
For Zolbetuximab requirements, pharmaceutical and biotechnology organizations should specify the required grade, biological form, quantity, analytical documentation and regulatory requirements. The appropriate quality specification should be confirmed before commercial supply.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | pH 6.0 |
| Water Content | NMT 1.0% |